With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain
Prostate cancer breakthrough as drug combo gives patients a powerful new chance
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study
‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to…
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a…
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given…
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the…
